Verona Pharma is a biopharmaceutical company that aims to improve the lives of those suffering from respiratory diseases by innovating therapeutic products. It was founded in 2005 in London, England. There proprietary lead candidate, RPL554 has opened a door to a whole new generation of drugs as it combines bronchodilator and an anti-inflammatory agent in a single compound. It has the potential to provide relief for the many patients suffering from respiratory conditions such as chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and possibly asthma. Verona Pharma is listed on the NASDAQ global market and is supported by investors from U.S, U.K and Europe.